Zenith Montel-Villorente

Mrs. Zenith Montel-Villorente

Maridan Industries, Inc.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ASAngelica Faith Suarez
Angelica Faith Suarez
ATApril Dawn Tirador
April Dawn Tirador
Zenith Montel-VillorenteZenith Montel-Villorente
Zenith Montel-Villorente
CBCathrina F. Bagarinao
Cathrina F. Bagarinao
Jan Vincent SollestaJan Vincent Sollesta
Jan Vincent Sollesta
Doralyn DalisayDoralyn Dalisay
Doralyn Dalisay
Honey exhibits antibacterial and antioxidant activities that are ascribed to its diverse secondary metabolites. In the Philippines, the antibacterial and antioxidant activities, as well as the bioactive metabolite contents of the honey, have not been thoroughly described. In this report, we investigated the in vitro antibacterial and antioxidant activities of honey from Apis mellifera and Tetragonula biroi, identified the compound responsible for the antibacterial activity, and compared the observed bioactivities and metabolite profiles to that of Manuka honey, which is recognized for its antibacterial and antioxidant properties. The secondary metabolite contents of honey were extracted using a nonionic polymeric resin followed by antibacterial and antioxidant assays, and then spectroscopic analyses of the phenolic and flavonoid contents. Results showed that honey extracts produced by T. biroi exhibits antibiotic activity against Staphylococcal pathogens as well as high antioxidant activity, which are correlated to its high flavonoid and phenolic content as compared to honey produced by A. mellifera. The bioassay-guided fractionation paired with Liquid Chromatography Mass Spectrometry (LCMS) and tandem MS analyses found the presence of the flavonoid isorhamnetin (3-methylquercetin) in T. biroi honey extract, which was demonstrated as one of the compounds with inhibitory activity against multidrug-resistant Staphylococcus aureus ATCC BAA-44. Our findings suggest that Philippine honey produced by T. biroi is a potential nutraceutical that possesses antibiotic and antioxidant activities.

23 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Lex Aliko Parel BalidaLex Aliko Parel Balida
Lex Aliko Parel Balida
JRJulia Theresa Regalado
Julia Theresa Regalado
JADE JOSHUA Rebaño TeodosioJADE JOSHUA Rebaño Teodosio
JADE JOSHUA Rebaño Teodosio
Kathryn Ann Herman DizonKathryn Ann Herman Dizon
Kathryn Ann Herman Dizon
ZSZhe Sun
Zhe Sun
Doralyn DalisayDoralyn Dalisay
Doralyn Dalisay
Cajanus cajan L. (pigeon pea, locally known in the Philippines as kadios) seed is a functional food with health benefits that extend beyond their nutritional value. C. cajan seeds contain highly diverse secondary metabolites with enriched beneficial properties, such as antibacterial, anticancer, and antioxidant activities. However, the antibacterial activities of secondary metabolites from Philippine-grown C. cajan, against multidrug-resistant Staphylococcus aureus have not been thoroughly described. Here, we investigated the in vitro antibacterial properties of C. cajan seed against multidrug-resistant S. aureus ATCC BAA-44 (MDRSA) and three other S. aureus strains (S. aureus ATCC 25923, S. aureus ATCC 6538, and coagulase-negative S. aureus) and, subsequently, identified the antibiotic markers against S. aureus strains using mass spectrometry. Secondary metabolites from C. cajan seeds were extracted using acetone, methanol, or 95% ethanol. Antibacterial screening revealed antibiotic activity for the C. cajan acetone extract. Bioassay-guided purification of the C. cajan acetone extract afforded three semi-pure high-performance liquid chromatography (HPLC) fractions exhibiting 32–64 µg/mL minimum inhibitory concentration (MIC) against MDRSA. Chemical profiling of these fractions using liquid chromatography mass spectrometry (LCMS) identified six compounds that are antibacterial against MDRSA. High-resolution mass spectrometry (HRMS), MS/MS, and dereplication using Global Natural Products Social Molecular Networking (GNPS)™, and National Institute of Standards and Technology (NIST) Library identified the metabolites as rhein, formononetin, laccaic acid D, crotafuran E, ayamenin A, and biochanin A. These isoflavonoids, anthraquinones, and pterocarpanoids from C. cajan seeds are potential bioactive compounds against S. aureus, including the multidrug-resistant strains.

10 February 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
JADE JOSHUA Rebaño TeodosioJADE JOSHUA Rebaño Teodosio
JADE JOSHUA Rebaño Teodosio
Kathryn Ann Herman DizonKathryn Ann Herman Dizon
Kathryn Ann Herman Dizon
JBJulyanna R. Bruna
Julyanna R. Bruna
Jan Vincent SollestaJan Vincent Sollesta
Jan Vincent Sollesta
Zenith Montel-VillorenteZenith Montel-Villorente
Zenith Montel-Villorente
Doralyn DalisayDoralyn Dalisay
Doralyn Dalisay
Background/Objectives: The global rise in multidrug-resistant Staphylococcus aureus (MDR-SA) threatens the efficacy of existing antibiotics and necessitates alternative antibacterial strategies. Plant-derived isoflavones represent a promising but underexplored source of novel antimicrobials. Biochanin A, isolated from Cajanus cajan seeds, exhibits antibacterial activity and may act via noncanonical mechanisms. This study elucidates the mechanism of action and safety profile of Biochanin A against MDR-SA using integrated experimental and computational approaches. Methods: Antibacterial activity was assessed by minimum inhibitory concentration (MIC) testing. Membrane integrity and morphological alterations were evaluated using flow cytometry and scanning electron microscopy (SEM), respectively. Target gene modulation was analyzed by qRT-PCR, while molecular interactions were examined through in silico docking. Cytotoxicity was evaluated in normal mammalian kidney, liver, and cardiac cells. Results: Biochanin A inhibited MDR-SA with an MIC80 of 64 µg/mL. Flow cytometry showed membrane disruption in 74.46 ± 13.19% of treated cells, and SEM revealed a 20% reduction in cell size (561.95 ± 21.99 nm). Biochanin A markedly downregulated femA (94%) and femB (67%), with minimal effect on femX (10%). Docking analyses supported preferential binding to FemA (−7.7 kcal/mol) and FemB (−7.5 kcal/mol) proteins. No cytotoxic effects were observed in normal mammalian cells. Conclusions: Biochanin A is a promising plant-derived antibacterial candidate against MDR-SA, targeting key cell wall biosynthesis genes while maintaining mammalian safety. These findings position Biochanin A as a viable lead for further biochemical, structural, and in vivo pharmacological validation, highlighting the translational potential of plant-derived isoflavones in combating antibiotic resistance.